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A procedure for discrimination between scrapie and bovine spongiform encephalopathy (BSE) in sheep is of
importance for establishing whether BSE has entered the sheep population. Since BSE has not yet been found
in sheep at the farm level, such discrimination procedures can be developed only with experimental sheep BSE.
Two distinctive molecular features of the prion protein (PrP)—molecular size and glycosylation profile—in
proteinase K digests of brain stem tissue from sheep were used here; upon Western blotting, these features led
to an unequivocal discrimination among natural scrapie, experimental scrapie, and experimental BSE. The
higher electrophoretic mobility of PrP in sheep BSE could be best observed after deglycosylation treatment
with N-glycosidase F. A simpler method for confirmation of this size difference involved comparison of the
ratios for the binding of two monoclonal antibodies: P4 and 66.94b4. Based on epitope mapping studies with
P4 and peptides, it appeared that N-terminal amino acid sequence WGQGGSH was intact only in sheep scrapie
digests. Another feature typical for PrP in sheep BSE was the large fraction of diglycosylated PrP (70% or
more). These data were obtained for a large group of positive sheep, consisting of 7 sheep with experimental
BSE infection (genotypes: six ARQ/ARQ and one AHQ/AHQ), 48 sheep naturally infected with scrapie (six
different genotypes), and 3 sheep with primary experimental scrapie infection. Routine tests of slaughter
material serve well for the initial detection of both BSE and scrapie. With Western blotting as a rapid follow-up
test, a 66.94b4/P4 antibody binding ratio above 1.5 is a practical indicator for serious suspicion of BSE
infection in sheep.
Transmissible spongiform encephalopathies (TSEs), such as
bovine spongiform encephalopathy (BSE) in cattle and scrapie
in sheep, represent a unique class of infectious diseases for
which the mechanism of infection is mainly unknown. Infec-
tions are accompanied by the accumulation of an altered form
(PrPSc) of the host prion protein (PrPC), a glycoprotein that is
expressed predominantly in neuronal tissues. The unusual
properties of the agent have led to the concept that it consists
only of protein (29). The most important hallmark is the partial
resistance of PrPSc to degradation by endoproteinases, such as
proteinase K (PK). Depending on host species and TSE strain,
PK removes 55 to 70 residues from the N-terminal domain of
PrPSc, yielding a distinct product, PrPres, which consists mainly
of three glycoforms: aglycosyl, monoglycosyl, and diglycosyl
fractions (5, 19, 27, 28, 30). The relative concentrations of
these three glycoforms (glycosylation profile) are used as bio-
chemical targets for discriminating infecting TSE agents (12,
18).
The risk that the agent causing BSE may have entered the
sheep population has serious implications for human health
following compelling evidence that BSE in cattle and a variant
form of Creutzfeldt-Jakob disease in humans share a common
source of agent (3, 9, 18, 26, 43). For reasons of consumer
safety as well as disease control at the farm level, it is of
eminent interest that reliable tests be developed for the iden-
tification of sheep BSE. These tests should also be cost-effec-
tive, fast enough for screening at the slaughter line, and appli-
cable for flock certification. Since BSE has not yet been found
in sheep at the farm level, such procedures can be developed
only with experimental sheep BSE.
Promising results for discriminating sheep scrapie and ex-
perimental sheep BSE in the clinical phase of the disease have
been obtained with Western blotting, an effective technique for
detection of the three glycoforms of PrPres with PrP-specific
antibodies. The molecular size of the aglycosyl fraction of
PrPres from the brain is one of the targets for discriminating
between the two types of infection but yields partly conflicting
results. Most Western blotting studies of sheep brain have
reported a larger size for the aglycosyl fraction of PrPres in
sheep with natural scrapie than in sheep with experimental
BSE (1, 17, 22, 35), while one study showed contradictory
examples of either smaller or larger sizes for the aglycosyl
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fraction of PrPres in natural scrapie cases (20). Unfortunately,
the aglycosyl fraction has the lowest concentration of the three
glycoforms of PrPres, making this approach less attractive for
routine diagnosis, unless an additional deglycosylation treat-
ment, e.g., with N-glycosidase F (PNGaseF), can yield a more
homogeneous discrimination based on size differences. Other
features used for discrimination in Western blotting are the
type of PrP-specific antibodies and the glycosylation profile of
PrPres. Stack et al. (35) reported in a limited study that mono-
clonal antibody P4 has an affinity for PrPres in natural sheep
scrapie but hardly reacts with that in experimental sheep BSE,
while monoclonal antibody 6H4 does clearly bind PrPres in
both kind of infections. Furthermore, a higher relative concen-
tration of diglycosylated PrPres in BSE-infected sheep than in
sheep with natural scrapie infection has been reported (35),
although in other reports the concentrations of diglycosylated
PrPres were similar for the two disease entities (1, 17).
Scrapie in sheep is much more heterogeneous than BSE in
cattle. While for scrapie over 10 different strains have been
identified in mouse bioassays, BSE in cattle has until now
yielded only 1 strain (8). Also, while in cattle no genetic linkage
has been found yet, the susceptibility of sheep to scrapie has
been found to be genetically linked to distinct polymorphisms
in the PrP gene, notably, in codons 136 (A or V), 154 (R or H),
and 171 (Q, R, or H), with ARQ (A136R154Q171) being the
phylogenetic wild type (4, 21). Arginine at codon 171 is linked
to very low susceptibility, while valine at codon 136 is linked to
enhanced susceptibility. When studying TSEs in sheep, one
should take into consideration factors such as PrP genotype,
breed, route, and origin of the infection (6).
The objective of this study was to develop a practical method
for Western blotting discrimination between experimental
sheep BSE and natural scrapie. This method was used for
PK-digested brain stem tissue from a large group of affected
sheep, consisting of 7 that were orally infected with BSE (PrP
genotypes: six ARQ/ARQ and one AHQ/AHQ) and 48 that
had natural scrapie infection (six different genotypes). In ad-
dition, three sheep orally infected with unpassaged sheep
scrapie, a goat with natural scrapie, and two bovine BSE sam-
ples were investigated. Deglycosylation with PNGaseF, epitope
mapping studies with different PrP-specific antibodies, com-
parative analysis of the ratios for the binding to PrPres of
monoclonal antibody P4 and novel monoclonal antibody
66.94b4, and determination of the glycosylation profile were
explored.
MATERIALS AND METHODS
Animals and tissues. The sheep used in this study are described in Table 1.
TSE status was confirmed by histopathologic and immunohistochemical (IHC)
analyses. Four homozygous sheep (genotype: ARQ/ARQ) were orally infected
with a pool of BSE-infected cattle brain as follows. Texel or Texel cross ewes
were maintained and mated in a closed environment where scrapie had not
occurred in the past 5 years. Offspring were weaned and transferred to an
experimental pathogen class 3 unit at 4 to 5 months of age. Three weeks later,
these lambs were orally dosed with 25 ml of a 20% (wt/vol) brain stem homog-
enate by using disposable syringes. The brain stem homogenate was prepared
from approximately 50 brain stems originating from confirmed BSE-infected
British cattle. Samples of the same brain stem homogenate pool were used for
transmission experiments with Romney sheep (23, 24, 35). The BSE-infected
sheep developed clinical signs (ataxia, tremors at the head, and a positive nib-
bling reflex) at 20, 21, 23, and 24 months after oral dosing. These sheep were
euthanatized within 14 days after the onset of clinical signs.
Sheep with natural scrapie (n  48) originated from 13 farms randomly
distributed throughout The Netherlands; 11 sheep were from a single farm, and
18 were from an open flock at the Central Institute for Animal Disease Control,
Lelystad, The Netherlands. One sheep (ARQ/ARH) without clinical signs or
brain pathology was diagnosed with preclinical scrapie by IHC analysis of ton-
sillar tissue (34, 38, 40). Four sheep which were confirmed to be negative by
testing of tonsillar and brain tissues were included. The breed of the animals was
Texel or Texel cross, except for one, which was a Flemish breed.
All animals were euthanatized between January 1999 and February 2002.
When known, ages varied between 15 and 108 months. Euthanasia by exsangui-
nation was carried out after anesthesia was applied by intravenous injection with
sodium pentobarbital (Nembutal; Ceva Sante Animale BV, Libourne, France).
Blood samples were collected for genotyping. At necropsy, the brain was dis-
sected sagitally approximately 3 mm from the medial line. For histologic analysis,
the larger part of the brain and the medulla oblongata at the level of the obex
were fixed in phosphate-buffered formalin (10%). The smaller part of the brain
and the brain stem were frozen to below 20°C and used to prepare homoge-
nates.
Brain stem samples from three BSE-infected sheep (two with genotype ARQ/
ARQ and one with genotype AHQ/AHQ) were obtained from the Veterinary
TABLE 1. Sheep used in this study
Group of sheep No. ofsheep Genotype Sheep breed
a TSE inoculumb Disease status attissue collection
Experimentally infected (oral route) 4 ARQ/ARQ Texel or Tex.cr. Cow BSE Clinical signs
2 ARQ/ARQ S.C. Cheviot Cow BSEc Clinical signs
1 AHQ/AHQ S.C. Cheviot Cow BSEc Clinical signs
3 VRQ/VRQ Cheviot Sheep scrapied Clinical signs
Naturally infected with scrapie 5 ARQ/ARQ Texel or Tex.cr. Clinical signs
20 VRQ/ARH Texel or Tex.cr. Clinical signs
10 VRQ/ARQ Texel or Tex.cr. Clinical signs
4 VRQ/ARR Texel or Tex.cr. Clinical signs
1 VRQ/ARR Flemish Clinical signs
7 VRQ/VRQ Texel or Tex.cr. Clinical signs
1 ARQ/ARH Texel or Tex.cr. Healthy, preclinical signs
Negative control 2 ARQ/ARQ Texel or Tex.cr. Unknown
1 VRQ/ARR Texel or Tex.cr. Clinically suspect
1 ARH/ARR Texel or Tex.cr. Clinically suspect
a Tex.cr., Texel cross; S.C. Cheviot, South Country Cheviot.
b All inocula originated from the United Kingdom.
c BSE-infected cattle brain pool different from that used for Texel or Texel cross sheep.
d Natural sheep scrapie brain pool from 17 sheep.
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Laboratories Agency—Weybridge; they had been generated in South Country
Cheviot sheep (13). These animals had been infected through the oral route with
a brain pool (composed of six cow brains) different from that used above but
similar to those used in other described cases (17, 20; N. Hunter and J. Foster,
personal communication). Brain samples—partly from the thalamus and partly
from the basal nuclear region—were also obtained from three sheep experimen-
tally infected with scrapie (genotype VRQ/VRQ Cheviot sheep bred in isolation
in the United Kingdom from New Zealand-born ewes). These animals had been
orally infected with 1 g of a brain pool composed of whole brains from 17
scrapie-infected sheep either homozygous or heterozygous for the VRQ and
ARQ alleles.
One Dutch cow with clinical signs of BSE and a goat with scrapie, both
confirmed to be positive by IHC analysis and Western blotting, and the challenge
BSE inoculum itself were also included in the study.
Diagnostic confirmation. Confirmation of the TSE status for all animals was
performed by histopathologic analysis to reveal spongiform lesions and IHC
analysis with polyclonal antibodies to ovine PrP sequences from positions 94 to
105 and positions 223 to 234 for sheep and cattle, respectively, to prove the
presence of PrP deposits (39, 42). In addition, the TSE status for the sheep, goat,
and cow was further evaluated by using a rapid test, routinely used for the
diagnosis of BSE and scrapie, with monoclonal antibody 6H4 (Prionics Check;
Prionics A.G., Zu¨rich, Switzerland) (25, 33).
Special reagents. PNGaseF either was obtained as a recombinant product
from Escherichia coli (1,000 U/ml, 25,000 U/mg; Roche Diagnostics, Mannheim,
Germany) or was produced from Flavobacterium meningosepticum (500,000
U/ml, 1,800,000 U/mg; New England Biolabs, Beverley, Mass.).
Genotyping. Blood from sheep was used for PrP genotyping at least for PrP
codons 131, 154, and 171 (7). Because samples were collected over a period of
several years, a variety of genotyping techniques were used (denaturing gradient
gel electrophoresis, TaqMan analysis, and/or sequencing) (7; A. Bossers, unpub-
lished data). The DNA sequence of PrP in animals that were experimentally
infected with BSE was fully determined by sequencing. In addition to the tech-
niques mentioned, samples from all natural scrapie cases were genotyped again
by using a novel method (Pyrosequencing AB, Uppsala, Sweden) that approxi-
mately reveals mutations between codons 135 and 139, 152 and 156, and 170 and
173 (32; Bossers, unpublished).
Tissue treatments. All activities were carried out in a pathogen class 3 facility
in agreement with European Union directives and the guidelines set out by the
Spongiform Encephalopathy Advisory Committee in the United Kingdom.
For experiments with deglycosylation treatments, procedures for homogeni-
zation, digestion, and detection were as follows. Tissue homogenates (10%) were
prepared by homogenizing 0.3 to 0.6 g of brain stem material cut from within
3 cm of the obex region at 30,000 rpm for 60 s in extraction solution (0.01 M
Tris-HCl– 0.15 M NaCl– 5 mM EDTA [pH 8.0], 1% [wt/vol] Triton X-100, 0.5%
[wt/vol] sodium deoxycholate) by using an Omni International TH mixer with a
disposable probe. Digestion of 200 l of homogenates was carried out at 37°C for
1 h by the addition of 20 l of PK (0.55 mg/ml; E. Merck AG, Darmstadt,
Germany) in phosphate-buffered saline (PBS). Digestion was stopped by the
addition of 20 l of 125 mM Pefabloc SC (Roche). For further deglycosylation,
120 l of this digest was further denatured by adding 60 l of extraction solution
and 18 l of denaturing solution (5% sodium dodecyl sulfate [SDS]– 10%
-mercaptoethanol in 20 mM Tris-HCl– 150 mM NaCl– 2 mM EDTA [pH 7.5])
and then heating the mixture for 10 min at 95°C. From this mixture, 100 l was
taken and combined with 125 l of PBS and 25 l of 10% Triton X-100.
Deglycosylation was carried out for 16 h at 37°C by the addition of 3 U of
PNGaseF (1 U/l; Roche). Before application to gels, the PNGaseF-treated
sample (PNGaseF digest) and 120 l of the PK-treated sample (PK digest) were
precipitated with 1 ml of cold (20°C) methanol and centrifuged in a Microfuge
for 10 min at 16,000 x g. Pellets were dissolved by careful trituration with 100 l
of sample buffer (0.25 M Tris-HCl [pH 8.5], 2% lithium dodecyl sulfate, 2%
-mercaptoethanol, 0.4 mM EDTA, 0.02% bromphenol blue, 10% glycerol). The
samples were heated for 5 min at 96°C and used directly for SDS-polyacrylamide
gel electrophoresis (PAGE) (12% bis-Tris gels; NuPAGE; Invitrogen, Breda,
The Netherlands).
PrP-specific antibodies. The primary antibodies used were rabbit polyclonal
antibody R521 and mouse monoclonal antibodies P4, 6H4, and 66.94b4 (14, 16,
25, 39). Monoclonal antibody 66.94b4 has not been reported before and was
prepared by immunizing PrP knockout mice (10) (kindly provided by C. Weiss-
mann, Zu¨rich, Switzerland) with recombinant human PrP (produced in E. coli
and kindly provided by T. Sklaviadis, Thessaloniki, Greece) and recombinant
bovine PrP (Prionics). The antibody was found to be specific for intact PrPC and
PrPres; however, it did not bind 15-mer peptides of PrP sequences from various
animal species, as assessed by Pepscan analysis (see below). The linear epitope
specificities of the other antibodies, including 6H4, could be confirmed.
SDS-PAGE, Western blotting, and 66.94b4/P4 antibody binding ratios. SDS-
PAGE under reducing conditions was performed with 10-well precast 12%
NuPAGE gels (NuPAGE gel electrophoresis system; Invitrogen). The molecular
weight markers used were bovine serum albumin, chicken egg albumin, carbonic
anhydrase, and -lactalbumin (Sigma, St. Louis, Mo.). The sample volume ap-
plied was usually 10 l, representing 400 to 1,000 g of tissue equivalents.
Electrotransfer to polyvinylidene difluoride membranes (Immobilon-P; Milli-
pore, Bedford, Mass.) and immunostaining were performed according to estab-
lished procedures (11, 37). The primary antibodies used were mouse monoclonal
antibodies 6H4, P4, and 66.94b4 at 0.2 g/ml and rabbit polyclonal antibody
R521 at 1/2,000 in 50 mM Tris-HCl– 0.15 M NaCl– 2.5 mM KCl–0.05% Tween
20–5% skim milk protein (antibody incubation solution). The secondary anti-
bodies used were rabbit anti-mouse immunoglobulin G (IgG; Dako, Glostrup,
Denmark) and goat anti-rabbit IgG (Zymed Laboratories, San Francisco, Calif.),
both conjugated to alkaline phosphatase. The signals were developed with CDP-
Star by following the supplier’s instructions (Tropix, Bedford, Mass.) and were
recorded on photographic film (Hyperfilm ECL; Amersham, Buckinghamshire,
United Kingdom). The densities of the bands were recorded from the film with
an Agfa Duoscan T200XL scanner, further processed with GelPro software
(MediaCybernetics, Silver Spring, Md.), and expressed as integrated optical
densities. To calculate 66.94b4/P4 antibody binding ratios, integrated optical
densities obtained for both antibodies in the same experiment and from films
with similar exposure times were used. Molecular weights were determined
according to a method described previously (41).
Pepscan analysis. To detect the linear epitope specificities of the antibodies
used, Pepscan analysis of solid-phase synthetic peptides bound as described
previously was performed in an enzyme-linked immunosorbent assay-like setup
(14, 15). Complete sets of overlapping 15-mer peptides which covered the amino
acid sequences of bovine PrP and ovine PrP (respective GenBank accession
numbers AJ000739 and X55882) were synthesized. A site was considered positive
(i.e., antigenic) when the absorbance values of two or more consecutive peptides
were at least three times the background. The background was calculated as the
mean absorbance value measured for 20 consecutive peptides with low levels of
reaction, where the standard deviation (SD) was 20% the mean absorbance
value.
Peptide synthesis. Peptides with acetylated and amidated termini were syn-
thesized by using 9-fluorenylmethoxy carbonyl chemistry as previously described
(39). The products used were checked for identities by molecular mass spec-
trometry and were brought to over 80% purity by high-performance liquid
chromatography, as evaluated by photospectroscopy at 215 nm. Sequences were
based on that of ovine PrP. The peptides used were ovPrP89– 107, ovPrP94– 105,
ovPrP109– 136Ala136, ovPrP126– 143Ala136, and ovPrP223– 234.
Antibody blocking studies. For blocking experiments, polyclonal antibody
R521 (diluted 1/100 in PBS– 0.02% Tween 80) and murine monoclonal antibody
P4 (at 14 g/ml) were incubated overnight with 1 mg of peptide/ml at 4°C.
Subsequently, the mixtures were further diluted in antibody incubation solution
to a 1/2,000 dilution and to 0.2 g of mouse IgG/ml, respectively.
Statistical analyses. One-way analyses of variance were carried out to establish
whether variations between groups of data were greater than expected; if so,
subsequent differences between pairs of groups were considered significant if the
probability of a difference was 0.05 in multiple-comparisons tests either ac-
cording to the Student-Newman-Keuls test or, if differences among SDs were
found to be significant by Bartlett’s test, according to the nonparametric Welch
test. The software used for these calculations was Instat Statistics from Graph-
Pad Software, San Diego, Calif.
RESULTS
Improving the detection of differences in the migration of
PrPres in BSE- and scrapie-infected tissues. Upon routine
detection of PrPres in brain stem homogenates from sheep
infected with scrapie and BSE, typically three protein bands
(PrP triplet) were observed (Fig. 1A). These three bands rep-
resent the diglycosyl, monoglycosyl, and aglycosyl moieties. A
small but reproducible difference in molecular masses was vis-
ible between natural scrapie and experimental BSE for each of
the PrP triplet bands. The apparent molecular masses (mean
and SD) of the protein moieties in a typical experiment were
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26.3  0.5, 21.4  0.2, and 18.1  0.3 kDa for PrPres in
scrapie-infected sheep (n  3) and 25.5  0.5, 20.1  0.3, and
16.5  0.2 kDa in BSE-infected sheep (n  4). As is typical for
PrPres, the two glycosyl moieties appeared very diffuse, and the
aglycosyl form was often faint. However, the aglycosyl band
exhibited the sharpest profile and the largest visible migra-
tional difference between scrapie- and BSE-infected samples.
For practical diagnostic reasons, we tried to concentrate all
PrPres material in one band by enzymatic deglycosylation.
Upon deglycosylation with PNGaseF, which cleaves the N-
glycosidic bond between a complete carbohydrate moiety and
peptidyl asparagine, most of the diglycosylated PrPres and
monoglycosylated PrPres disappeared. Importantly, the migra-
tion position of the aglycosyl band was not changed detectably
by deglycosylation treatment (Fig. 1B). However, the deglyco-
sylation was often not complete. Attempts to improve the
extent of deglycosylation with PNGaseF failed. Attempts in-
cluded increasing the enzyme concentration to up to 20 U per
digest, using two sources of enzyme (recombinant from E. coli
or authentic from the host, F. meningosepticum), adding fresh
aliquots of enzyme at different intervals, and extending the
incubation time to up to 72 h (data not shown). Nevertheless,
in all samples tested so far, the aglycosyl band became more
intense after the PNGaseF treatment, a finding which is ad-
vantageous for discrimination between sheep infected with
natural scrapie and sheep infected with experimental BSE
when migrational differences between these two are used as
the sole method of detection.
Application of different antibodies to scrapie- and BSE-
infected tissue homogenates. Brain stem samples from BSE-
infected sheep were compared with brain stem samples from
scrapie-infected sheep by using four different PrP-specific
antibodies for material that had been digested with PK and
PNGaseF. While PrP-specific antibodies 6H4, P4, 66.94b4, and
R521 all bound the PrP triplet bands of PrPres in Western
blots, it appeared that antibodies 6H4, 66.94b4, and R521 each
revealed the same enhanced migrational differences between
samples from BSE-infected sheep and samples from scrapie-
infected sheep (Fig. 2, lanes 1 and 2). Monoclonal antibody P4
exhibited two aberrant aspects: first, the antibody hardly bound
to PrP in samples from BSE-infected sheep; second, when
samples were slightly reactive with P4, the migration positions
for the PrPres moieties in sheep BSE were similar to those in
sheep scrapie. In addition, antibodies P4 and R521 both
showed hardly any affinity for PrPres in bovine BSE (Fig. 2,
lanes 3).
Comparisons of natural sheep scrapie, experimental sheep
BSE, experimental sheep scrapie, and natural bovine BSE.
The differences in PrP migration and antibody binding be-
tween sheep scrapie and sheep BSE were observed in all seven
orally infected BSE sheep, irrespective of breed (Texel, Texel
cross, or Cheviot) or PrP genotype (six ARQ/ARQ and one
AHQ/AHQ) (Fig. 3A). The migration of PrPres in samples
from Cheviot VRQ/VRQ sheep orally infected with an unpas-
saged brain pool (from scrapie) was similar to that in samples
from sheep with natural scrapie infection (Fig. 3B). Thus, while
antibodies 66.94b4, 6H4, and R521 bound PrPres in samples
from both scrapie and BSE-infected sheep, P4 only bound well
to samples from scrapie-infected sheep.
For bovine BSE, the aglycosyl band of PrPres in brain stem
samples exhibited migration intermediate between those for
sheep scrapie and sheep BSE; this finding was most evident
after deglycosylation (Fig. 1C). This finding was obtained both
with the inoculum used for BSE-infected sheep (from the
United Kingdom) and for Dutch bovine BSE (data not shown).
Epitope characterization of antibodies P4 and R521 with
synthetic peptides. Based on the observations described above,
it appears that R521 binds well to PrPres in both natural scrapie
and sheep BSE, whereas P4 binds well only to PrPres in natural
scrapie (and hardly at all to PrPres in sheep BSE). Since P4 and
R521 were elicited against partial overlapping peptide se-
quences—positions 89 to 104 and positions 94 to 105 of ovine
FIG. 1. Migration patterns for PrPres in natural scrapie, experimen-
tal sheep BSE, and bovine BSE. (A) Sheep scrapie and sheep BSE
(sBSE). The three glycosylation forms of PrPres, diglycosyl, monogly-
cosyl, and aglycosyl, are indicated by arrows, from top to bottom,
respectively. (B) Comparison of migration positions for PrPres triplet
bands before and after PNGaseF treatments. The positions of the
aglycosyl band before () and after () deglycosylation by PNGaseF
appear to be identical. An additional band below the aglycosyl form is
variably present depending on the individual sample. (C) Differences
in the migration of the PrPres triplet in sheep scrapie, bovine BSE
(bBSE), and sBSE without () and with () PNGaseF treatments.
Molecular mass markers were 29 and 18.4 kDa, and their migration
positions are indicated by the upper and lower bars, respectively,
beside the panels. The procedures used were the Prionics Check
method (antibody 6H4) (A) and the methods designed for tissue treat-
ment and Western blotting for this study (antibody 66.94b4) (B and
C). Applied tissue equivalents were 430 g (A) and 500 g (with
PNGaseF) and 1,000 g (without PNGaseF) (B and C).
FIG. 2. Four different antibodies tested for three ruminant TSE
types. Lanes 1 to 3 contain PK digests of brain stem tissues infected
with natural scrapie, sheep BSE, and bovine BSE, respectively. West-
ern blotting of PK/PNGaseF digests was done with the antibodies
indicated above the panels. The applied tissue equivalent was 500 g
per lane. Molecular mass markers are as described in the legend to
Fig. 1.
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PrP, respectively—their requirements for binding to ovine PrP
were further investigated. Two sets of experiments were un-
dertaken. First, a Pepscan analysis of solid-phase 15-mer pep-
tides based on the ovine PrP sequence revealed that P4 bound
peptides around the core sequence 93WGQGGSH99 (Fig. 4).
The analysis of R521 was previously described (14): in a Pep-
scan analysis, this antiserum exhibited binding to three linear
sites in the PK-resistant region of PrPSc (the domain from
positions 94 to 105, which was used for immunization, and two
sequences in the domain from positions 121 to 146, which was
part of PrPres). In a second set of experiments, antibody block-
ing on Western blots was carried out with synthetic peptides in
solution to determine which amino acids in the ovine PrP
sequence contributed to binding of the antibodies to immobi-
lized protein. When ovine brain stem material was used, anti-
body P4 could be blocked fully by the peptide at positions 89 to
107 but not positions 94 to 105. R521 was already fully blocked
by the peptide at positions 94 to 105 (data not shown). Appro-
priate control peptides with sequences from other domains of
ovine PrP did not have any visible blocking effect (positions
109 to 136, 126 to 143, and 223 to 234). These results show that
the cleavage sites for proteases in PrPSc are different between
sheep scrapie and sheep BSE.
Antibody binding ratios for natural sheep scrapie, experi-
mental sheep scrapie, experimental sheep BSE, and natural
goat scrapie. In comparative Western blots with various con-
centrations of scrapie-infected sheep brain homogenates and
antibodies, antibody 66.94b4 exhibited a consistently higher
affinity for ovine PrPres than did antibody 6H4 (data not
shown). Therefore, 66.94b4 was used for further studies to
evaluate whether there were molecular differences between
groups of sheep with natural scrapie and sheep with experi-
mental scrapie or BSE. The molecular characteristics of PrPres
in our set of 48 sheep with natural scrapie were similar for all
six genotypes with respect to the migration positions of the
aglycosyl band and the antibody binding properties (66.94b4/
P4 ratio) for either the three PrPres bands together or the
aglycosyl band after PNGaseF treatment (Fig. 5). There were
also no significant differences when the theoretical effect of
overrepresentation by samples from a single herd was consid-
ered (data not shown). This possibility could be excluded by
analysis of two groups of sheep: a herd of 11 scrapie-infected
sheep from a single farm (all VRQ/ARH) and a group of 5
scrapie-infected sheep (VRQ/VRQ) from our own flock (data
not shown). A sample from a scrapie-infected goat was also
tested and did not show any visible difference from samples
obtained from sheep with natural scrapie infection for these
two properties.
FIG. 3. Different TSEs in sheep analyzed with antibodies 66.94b4
and P4. (A) Analysis of seven experimental sheep BSE cases. Lanes: 1,
natural scrapie; 2, BSE1, Texel; 3, BSE2, Texel; 4, BSE1, Cheviot
(AHQ/AHQ); 5, BSE2, Cheviot; 6, natural scrapie; 7, BSE3, Cheviot;
8, BSE3, Texel; 9, BSE4, Texel. (B) Analysis of three experimental
scrapie cases. Lanes: 1, BSE1, Texel; 2, natural scrapie (VRQ/VRQ);
3, experimental scrapie 1; 4, experimental scrapie 2; 5, BSE1, Texel; 6,
natural scrapie (VRQ/VRQ); 7, experimental scrapie 3; 8, natural
scrapie (VRQ/VRQ); 9, BSE1, Texel. Table 1 provides details on
experimentally infected animals. Applied tissue equivalents were 500
g (with [] PNGaseF) and 1,000 g (without PNGaseF). Molecular
mass markers are as described in the legend to Fig. 1.
FIG. 4. Epitope mapping of monoclonal antibody P4 by Pepscan
analysis with 15-mer solid-phase peptides overlapping the entire amino
acid sequence of the ovine PrP gene. Each bar represents the spectro-
photometric absorbance signal at one peptide. The peptides recog-
nized by the antibody are numbers 85 to 93 and 95. The common
sequence or core sequence between antigenic peptides 85 and 93 in
this analysis is 93WGQGGSH99 of ovine PrP. Numbers on the x axis
represent the N-terminal residue of each 15-mer peptide.
FIG. 5. Comparison of binding of antibody 66.94b4 and antibody
P4 in relation to individual scrapie isolates (including that from a
goat), a sheep BSE isolate, and different genotypes. Lanes: 1, VRQ/
VRQ; 2, VRQ/ARH; 3, VRQ/ARH; 4, ARQ/VRQ; 5, ARQ/ARH; 6,
ARQ/ARQ; 7, VRQ/ARH; 8, VRQ/ARH; 9, VRQ/ARH; 10, ARQ/
ARQ, BSE2, Texel; 11, VRQ/ARR; 12, ARQ/VRQ; 13, ARQ/ARQ,
sheep was scrapie negative but clinically suspect; 14, ARQ/ARH,
sheep with preclinical scrapie (clinically negative, tonsil positive, and
brain negative); 15, VRQ/ARR; 16, goat with scrapie; 17, ARH/ARR,
healthy sheep; 18, ARQ/VRQ; 19, ARQ/ARQ, BSE2, Texel. Half of
the samples were subjected to PNGaseF treatment. Applied tissue
equivalents were 1,000 g (without PNGaseF) and 500 g (with []
PNGaseF). Molecular mass markers are as described in the legend to
Fig. 1.
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To further substantiate these observations for the antibody
binding properties, density values were calculated for the
PrPres bands and transformed to 66.94b4/P4 ratios (Table 2).
The 66.94b4/P4 ratios obtained with sheep naturally and ex-
perimentally infected with scrapie were similar, both for the
three bands together after PK digestion only and for the agly-
cosyl band after subsequent PNGase F treament. In addition,
differences in these ratios among the six genotypes in sheep
naturally infected with scrapie were not statistically significant.
The ratios in samples from BSE-infected sheep, however, were
well above 1.5 and were significantly different from those in
samples from scrapie-infected sheep, which all remained below
this value (Table 2).
Glycosylation profiles. Glycosylation profiles were analyzed
as a possible independent parameter for strain differences (Fig.
6). In our set of samples, the relative concentration of digly-
cosylated PrPres in the PrP triplet was significantly higher in
samples from BSE-infected sheep (mean and SD, 76.9% 
5.2%; range, 77 to 85%; n  7) than in samples from scrapie-
infected sheep (mean and SD, 55.9%  6.0%; range, 46 to
71%; n  48) (P  0.001). The concentrations of the mono-
glycosyl and aglycosyl fractions of PrPres were also significantly
lower in BSE-infected sheep than in scrapie-infected sheep
(P  0.001). The three samples from sheep experimentally
infected with scrapie had the lowest concentration of the dig-
lycosyl form and the highest concentrations of both the mono-
glycosyl and the aglycosyl forms. There were also no statisti-
cally significant differences in glycosyl form concentrations
among sheep with different genotypes when the theoretical
effect of overrepresentation by samples from a single herd was
considered. In the sample from the goat infected with scrapie,
the relative concentrations of the three PrPres bands appeared
to be similar to those in the samples from sheep naturally
infected with scrapie.
FIG. 6. Triangular plot of individual glycosyl fractions of PrPres
after PK digestion for all TSE cases in sheep. In addition to the
individual data, the means for all sheep naturally infected with scrapie
(n  48), sheep experimentally infected with scrapie (n  3), and
sheep experimentally infected with BSE (n  7) are plotted with their
means and SDs. Symbols: triangles, sheep BSE; circles, natural sheep
scrapie; squares, experimental sheep scrapie. The values for sheep
BSE differed significantly (P  0.001) from those for natural sheep
scrapie and experimental sheep scrapie. Furthermore, the values for
the diglycosyl and monoglycosyl fractions in experimental sheep
scrapie deviated significantly from those in natural sheep scrapie (P 
0.01). Measurements from density scans were obtained as described in
Materials and Methods. Explanation for reading the plot: read the
values for the diglycosyl, monoglycosyl, and aglycosyl fractions over
lines parallel to the base, the left axis, and the right axis of the triangle,
respectively. For each point, the sum of the three values is 1. One in-
dividual point has been marked by arrows: its values are 61, 32, and 7%
for the diglycosyl, monoglycosyl, and aglycosyl fractions, respectively.
TABLE 2. Antibody binding ratios for PrPres in sheep scrapie, goat scrapie, and sheep BSEa
Group TSE type Genotype(no. of animals)
Mean  SD 66.94b4/P4 ratio in:
Three PrPres
bands
Aglycosyl band after
PNGaseF treatment
Natural scrapie Sheep scrapie All (48) 0.42  0.22b 0.74  0.27c
ARQ/ARQ (5) 0.53  0.12 0.99  0.24
ARQ/VRQ (10) 0.39  0.18 0.73  0.28
ARQ/ARH (1) 0.51 1.06
VRQ/ARH (20) 0.33  0.22 0.64  0.24
VRQ/VRQ (7) 0.52  0.27 0.71  0.25
VRQ/ARR (5) 0.53  0.19 0.84  0.23
Goat scrapie NA 0.99 1.08
Experimental TSE in sheep Scrapie VRQ/VRQ (3) 0.29  0.12 0.62  0.10
BSE in Texel or Tex.cr. All (7) 3.29  1.00d,f 12.59  7.84e,f
ARQ/ARQ (4) 3.09  1.05 12.34  5.76
BSE in S.C. Cheviot ARQ/ARQ (2) 3.35  1.45 6.24  0.09
BSE in S.C. Cheviot AHQ/AHQ (1) 3.98 26.30
a Ratios were obtained from density recordings as described in Materials and Methods. NA, not applicable; Tex.cr., Texel cross; S.C. Cheviot, South Country Cheviot.
b Range, 0.07 to 1.02.
c Range, 0.15 to 1.38.
d Range, 1.95 to 4.47.
e Range, 6.17 to 26.30.
f The value is statistically different from that in the following groups: the 48 natural scrapie cases, the 5 multimember-genotype natural scrapie cases, and the
experimental scrapie cases (P  0.001).
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Finally, there was no obvious correlation between a rela-
tively high affinity of P4 for scrapie PrPres (as reflected by a low
66.94b4/P4 antibody binding ratio) and the relative concentra-
tion of one of the three PrPres bands (data not shown).
DISCUSSION
This study shows that Western blotting of brain stem ho-
mogenates can be used as a rapid means for the diagnosis of a
suspected case of BSE in sheep and provides a practical
method for obtaining such a diagnosis. This study also extends
previous reports which reached basically the same conclusion,
but the experiments done here did not produce false-negative
diagnoses and were based on a comparison of samples from a
large group of sheep infected with scrapie and fully PrP geno-
typed. Three aspects of PrPres can be used as a basis for
suspicion: enhanced electrophoretic migration, very poor bind-
ing of antibody P4 to PrPres (relative to that of antibody
66.94b4), and a typical glycoprofile with a high concentration
of the diglycosyl fraction. Because the antibody comparison is
the most robust, a method for routine diagnosis based on this
aspect is suggested.
Of the three molecular mass forms of PK-resistant protein
PrPres, the form with the lowest molecular mass—representing
the aglycosyl fraction of PrPres—is approximately 1.6 kDa
smaller in sheep BSE than in sheep scrapie and is the best form
to use if diagnosis is to be based solely on enhanced electro-
phoretic migration. The reason is that for the two other forms,
the differences between BSE and scrapie are smaller than 1.6
kDa and are difficult to assess with the naked eye because of
the diffuse nature of the bands caused by the presence of
glycosyl groups, which intrinsically convey molecular microhet-
erogeneity to glycoproteins. However, since the aglycosyl moi-
ety represents only 5 to 20% of total PrPres, the aglycosyl band
can be very faint or invisible upon routine diagnosis. Indeed, it
was found that enzymatic deglycosylation of the other two
triplet bands of PrPres—representing the diglycosyl and mono-
glycosyl fractions—by PNGaseF resulted in an unambiguous
diagnosis of BSE when appropriate controls for scrapie were
included in the experiment. Although such deglycosylation of-
ten is incomplete, the aglycosyl band becomes sufficiently
dense in routine diagnostic experiments.
Differential antibody binding is another aspect which can be
used for the detection of BSE in sheep. The relative amounts
of binding of two antibodies, including one (P4) which does not
bind to PrPres in sheep BSE but does in scrapie and one (such
as 66.94b4) which binds to PrPres in both sheep BSE and
scrapie, were quantitated by densitometric scanning. This anal-
ysis led to a cutoff value for the 66.94b4/P4 ratio of approxi-
mately 1.5 (at 0.2 g of IgG/ml for chemoluminescence detec-
tion), above which an animal should be considered to be BSE
positive, irrespective of whether enzymatic deglycosylation was
applied (Table 2). However, visual inspection alone is sufficient
to observe this difference in antibody binding (Fig. 3). The very
poor binding of antibody P4 to PrPres relative to that of anti-
body 66.94b4 in sheep BSE confirmed the findings of Stack et
al. (35), who compared the binding of antibodies P4 and 6H4
in a limited number of cases. Antibody 6H4 is comparable to
antibody 66.94b4 in that it is elicited with recombinant PrP and
binds to the PK-resistant domain of PrPSc. However, analysis
for linear epitopes (Pepscan analysis) showed that the speci-
ficity of 66.94b4 is profoundly different from that of 6H4; the
binding site of 6H4 is a linear one located at amino acids 148
to 156 of ovine PrP (25; this study), but that of 66.94b4 could
not be identified. These data indicate a conformation-depen-
dent epitope for 66.94b4. Our study included a larger number
of sheep, with respect to both sheep BSE and scrapie. It would
be valuable to know whether the material tested by Hope et al.
(20) would have yielded more consistent discrimination be-
tween natural scrapie and sheep BSE if P4 and 66.94b4 (or
another PrP-specific antibody, such as 6H4) had been used.
Another aspect which can be used for BSE detection is a
high concentration of the diglycosyl fraction (or a low concen-
tration of the aglycosyl fraction); this concentration was over
70% of total PrPres in the seven BSE-infected sheep studied,
while in scrapie-infected sheep, the concentration remained
below this value (71%). Like us in this study, Stack et al. (35)
also noted that the concentration of the diglycosyl fraction of
PrPres in two BSE-infected sheep was higher than that in nat-
ural scrapie-infected sheep, while Baron et al. (1, 2) and Hill et
al. (17) did not observe a clear difference. It is difficult to
explain these different observations. They probably do not
relate to differences in the region of the brain sampled (36) but
may be related more to the type and concentration of antibody
used. Furthermore, the data must be considered cautiously,
since there is a variation in SDs of 50 to 90% within repeated
measurements of individual samples. Not only antibody type
but also antibody concentration are of importance for stan-
dardizing such strain-specific details. Furthermore, if the gly-
cosylation profile is used to reach a diagnosis, it should be
performed with proper controls, such as samples representing
natural scrapie and experimental BSE, in the same blot; this
requirement is hardly possible for routine laboratories due to
the limited availibility of materials for sheep BSE. Neverthe-
less, our data indicate the same trend as has been observed by
others that the concentration of the diglycosyl PrP fraction is
relatively high in sheep BSE as well as BSE in other animal
species, including humans with a variant form of Creutzfeldt-
Jakob disease (12, 18, 31, 35).
The basis for the discrimination between scrapie and BSE in
sheep is the location of the N-terminal cleavage site in PrPres
by proteolytic digestion. This location was detailed by fine
epitope mapping of monoclonal antibody P4 in a Pepscan
analysis with solid-phase peptides, blocking studies with syn-
thetic peptides in solution, and a comparison with polyclonal
antiserum R521. With antibodies P4 and R521, which bind
ovine PrP at sites which overlap each other in the N-terminal
domain of PrPres, it was shown that digests of brain stem
samples from BSE-infected sheep contained a form of PrPres
which lacked amino acids needed for binding by P4. Antibody
P4 binds to residues 93 to 99 of ovine PrP, and this binding can
be blocked in Western blots for ovine scrapie by a peptide
(residues 89 to 107) containing the sequence from residues 93
to 99 but not by an overlapping peptide (residues 94 to 105)
lacking Trp93. Since the sequence from residues 93 to 99 is
required for optimal binding by P4, it is possible that also
amino acids 94 to 99 are absent in PrPres in sheep BSE (Fig. 7).
In contrast to antibody P4, antibody R521 binds PrPres in sheep
BSE very well. R521 was previously shown to bind broadly to
synthetic PrP sequences in this same region by a Pepscan
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analysis (14), and this binding could be fully blocked in West-
ern blots by a peptide containing residues 94 to 105; these
results confirm that somewhere in this region from residues 94
to 105, the N terminus of PrPres in sheep BSE is located. When
the results obtained with these two antibodies are considered
together with the 1.6-kDa size difference between the aglycosyl
fractions of PrPres in sheep BSE and sheep scrapie, it is most
likely that the cleavage of PrPSc in sheep BSE by proteases
such as PK occurs mainly in the region from residues 93 to 99
(sheep BSE cleavage site), while in sheep scrapie cleavage
occurs about 10 to 17 residues N terminal of this stretch of
amino acids (scrapie cleavage site). The low reactivity of P4
with PrPres in sheep BSE and the migration of PrPres in sheep
scrapie (Fig. 2) are best explained by the coexistence of a very
small population of PrPSc either in a sheep scrapie conforma-
tion or in another folded state which allows proteases to trim
PrPSc up to the sheep scrapie cleavage site (Fig. 7). Alterna-
tively, the P4-reactive bands could be the result of the incom-
plete action of PK on PrPSc, yielding a small fraction of larger
PrPres molecules.
Since this work was carried out with experimental BSE, it is
quite possible that PrPres from sheep with BSE in the field has
different biochemical characteristics. Nevertheless, there are a
number of factors which make this situation unlikely. We and
others used different sources of bovine BSE as an inoculum,
different sheep breeds, three different PrP genotypes, and
three different routes of infection (1, 17, 20, 22, 35); the results
for the brain consistently indicated a smaller molecular size for
PrPres bands in sheep BSE than in sheep scrapie. In addition,
we showed here that either natural or experimental infection in
sheep led to the same molecular PrPres phenotype typical for
scrapie, a finding which excludes the possibility that the route
of infection has an influence on the molecular behavior of
PrPSc. However, it would be helpful to determine how subse-
quent passages of sheep scrapie to sheep will behave, since the
phenotype of BSE in cattle might be the result of secondary
passages (3).
Of the three methods discussed above, diagnosis based on
differential antibody binding appears to be the most robust
approach for routine screening, since a simple visual inspection
leads to an unequivocal result. If the screening initially is per-
formed by a rapid test which is suitable for the detection of
both scrapie and BSE in sheep and yields a positive result, the
screening should be followed directly by this proposed double-
antibody test. So far, this type of analysis has been carried out
with different detergents and buffer types with pHs between 7
and 8, indicating that it is quite robust.
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